HOME > Reports - Events > (Event Report) The 2nd Global Expert Meeting of The “Rebalancing National Health Systems: Innovation and Sustainability” Series – The Current Status, Challenges, and Opportunities of Health Technology Assessment (HTA) in Japan

Health and Global Policy Institute(HGPI)- Reports

  • Events
  • Research
  • Interviews
  • Lestures & Media
  • Others
  •  

(Event Report) The 2nd Global Expert Meeting of The “Rebalancing National Health Systems: Innovation and Sustainability” Series – The Current Status, Challenges, and Opportunities of Health Technology Assessment (HTA) in Japan

date2017-10-05

The 2nd Global Expert Meeting entitled, “‘Rebalancing National Health Systems: Innovation and Sustainability’ Series – The Current Status, Challenges, and Opportunities of Health Technology Assessment (HTA) in Japan” was convened by Health and Global Policy Institute (HGPI) on Thursday, 5 October 2017.


In April 2017, the Center for Strategic and International Studies (CSIS) and HGPI jointly convened the very first global expert meeting on “Rebalancing National Health Systems: Innovation and Sustainability.” At this meeting, experts agreed that issues such as those related to containing costs while promoting innovation and ensuring equitable access to quality health care were not unique to Japan, but were wide-ranging challenges being faced around the globe. The meeting’s experts also emphasized the importance of involving the public (patients) in the decision-making process, especially when evaluating the costs and public health benefits of health technology.

In recent years, the sustainability of health systems has become a pressing threat worldwide due to rapid demographic and epidemiological transitions, ever-growing health expenditures, and new innovations in health care. At the same time, discussion is intensifying around the world questioning the concept of Universal Health Coverage (UHC), as well as the potential size of costs and benefits in health care systems with UHC. Japan has been exploring solutions to issues related to health care costs, such as the introduction of HTA and reinforcement of insurer functionality. However, Japan, just like many other countries around the globe, is faced at the challenge of how to accurately assess and reflect the values of everyone who receives medical services (including both society as a whole and individual people) into evaluations of medical technology, devices, and medications. 

In this 2nd global expert meeting, a variety of domestic and foreign experts and stakeholders discussed on the current status of HTA implementation in Japan, as well as future challenges for HTA and its potential advantages.


Keynote Speech 1
Yasuhiro Suzuki (Chief Medical & Global Health Officer, Vice-Minister for Health, Ministry of Health, Labour and Welfare (MHLW)


Keynote Speech 2
Shinya Saito (Professor, Graduate School of Health Sciences, Okayama University/ President, International Society for Pharmacoeconomics and Outcomes Research(ISPOR) JAPAN)


Roundtable “The Current Status, Challenges, and Opportunities of HTA in Japan”
Participants: (Honorifics and titles omitted, in no particular order)
Manabu Akazawa (Professor, Meiji Pharmaceutical University, Department of Public Health and Epidemiology)
Ataru Igarashi (Assistant Professor, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
Mamoru Ichikawa (Principal Program Director, Production Center I Science Programs Division, Program Production Department, Japan Broadcasting Corporation (NHK))
Eun-Young Bae (Professor, School of Pharmacy, Gyeongsang National University)
Yoshie Onishi (Director, Japan Operations, Creativ Ceutical)
Chris Hourigan (President, Janssen Pharmaceutical K.K.)
Kevin Haninger (Deputy Vice President, International Advocacy, Pharmaceutical Research and Manufacturers of America(PhRMA))
Koen Torfs (VP Global Reimbursement & Real World Evidence, Janssen Pharmaceutical Companies of Johnson & Johnson)
Yasushi Goto (Department of Respiratory Medicine, National Cancer Center Hospital)
Hidehito Kotani (President, Panasonic healthcare Holdings Co., Ltd., President, CEO, CTO, Panasonic Healthcare Co., Ltd.)
Shinya Saito (Professor, Graduate School of Health Sciences, Okayama University/ President, ISPOR JAPAN)
Naomi Sakurai (President, Cancer Solutions Co., Ltd. / Patient Representative, Cancer Control Promotion Council)
Takeru Shiroiwa (Senior Researcher, Department of Health and Welfare Services, National Institute of Public Health)
Makoto Tamura (Director, Medical Technology Policy Institute American Medical Device and Diagnostic Manufacturers’ Association (AMDD) / Founder and CEO, Healthcare System Planning Institute)
Hiroshi Nakamura (Professor, Business Environment, Graduate School of Business Administration, Keio University)
Ryu Niki (Adviser and Professor, Nihon Fukushi University)
Philippe Fauchet (Vice Chairman, European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan/ Chairman, GlaxoSmithKline K.K.))
Yoshiyuki Majima (President, Pancreatic Cancer Action Network Japan)
Junichi Matsumoto (Executive Board Member, Japan Medical Association)
Kaoru Manabe (Director, Medical Education Division, Ministry of Education, Culture, Sports, Science and Technology (MEXT))


Moderator:
Ryoji Noritake (President, Health and Global Policy Institute)


(Photographed by: Kazunori Izawa)

 
 

Page top

Back to Events